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ABSTRACT 
Aim: To examine metabolic factors that influence ketone production after sodium-glucose 
cotransport inhibitor (SGLT2) administration 
Research Design and Methods: Fasting plasma glucose, insulin, glucagon, free fatty acid and 
ketone concentrations were measured in 15 type 2 diabetes mellitus (T2DM) and 16 non-diabetic 
subjects before and at 1 and 14 days after treatment with empagliflozin. 
Results: Empagliflozin caused 38 mg/dl reduction in the fasting plasma glucose (FPG) 
concentration in T2DM patients. However, it caused only small but significant (7 mg/dl) 
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reduction in the FPG concentration in impaired fasting glucose (IFG) subjects and did not affect 
the FPG concentration in normal glucose tolerant (NGT) subjects. Empagliflozin caused a 
significant increase in the mean plasma glucagon, free fatty acid (FFA) and ketone 
concentrations in T2DM subjects. However, empagliflozin did not cause a significant change in 
the mean  plasma insulin, glucagon or ketone concentrations in non-diabetic subjects. An index 
which integrates the change in plasma glucose, insulin and FFA concentration at day 1 strongly 
correlates with plasma ketone concentration at day 1 (r=0.85, p<0.001) and day 14 (r=0.63, 
r=0.01) and predicts with 86% sensitivity and 83% specificity subjects at the top tertile for 
plasma ketone concentration after empagliflozin treatment.  
Conclusion: The results of the present study demonstrate that SGLT2 inhibition exert different 
metabolic effects in non-diabetic individuals compared diabetic patients.  
 
 
INTRODUCTION 
Sodium-glucose co-transport (SGLT2) inhibitors are a novel class of antidiabetic drugs approved 
by the Food and Drug Administration for the treatment of T2DM (1). Members of this class of 
drugs lower the plasma glucose concentration by inhibiting renal glucose transport and 
producing glucosuria (1-2). Because of their unique mechanism of action, SGLT2 inhibitors are 
effective in lowering the plasma glucose concentration as monotherapy and in combination with 
all other antidiabetic agents including insulin (2). Recent reports have demonstrated that some 
subjects receiving SGLT2 inhibitors experience clinically significant ketoacidosis events despite 
being normoglycemic (3-5). These euglycemic ketoacidotic events following SGLT2 
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administration were primarily reported in patients with type 1 diabetes (3,4), and in type 2 
diabetes as well (5).   
In addition to lowering the plasma glucose concentration, SGLT2 inhibitors exert multiple other 
metabolic actions in T2DM individuals (6). They improve insulin sensitivity (7) and beta cell 
function (8), stimulate an increase in the basal rate of hepatic glucose production, lower fasting 
plasma insulin concentration, stimulate glucagon secretion (7,9) and switch fuel consumption 
from glucose to fat oxidation (9,10). Some of these metabolic actions of SGLT2 inhibitors can 
affect ketone production in T2DM patients. Recently, we (10) and others (11) have demonstrated 
that administration of SGLT2 inhibitors for 2-4 weeks in T2DM patients caused significant 
increase in fasting plasma ketone concentration. To examine factors that regulate glucose and fat 
oxidation and could lead to the increase in plasma ketone concentration in T2DM patients, we 
have compared the effect of empagliflozin treatment on plasma glucose, insulin, glucagon, free 
fatty acid (FFA) and ketone concentration in T2DM and non-diabetic individuals before and 1 
and 14 days after treatment with empagliflozin.  
Research Design and Methods 
Subjects: 31 subjects who were part of study designed to examine the effect of empagliflozin on 
the kinetics of renal glucose handling participated in this study. 15 type 2 diabetic subjects, and 
16 non-diabetic (8 with normal fasting glucose [FPG <100 mg/dl]; and 8 with impaired fasting 
glucose [FPG=100-125 mg/dl])subjects according to the American Diabetes Association criteria. 
All subjects were in good general health as determined by medical history, physical exam, 
screening lab tests, and EKG.  Body weight was stable (±3 pounds) in all subjects for 3 months 
prior to study and no subject participated in any excessively heavy exercise program. Patients 
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with T2DM were on a stable dose of metformin and/or sulfonylurea . None of the non-diabetic 
subject was taking any medication known to affect glucose metabolism. 
After screening, eligible subjects received measurement of fasting plasma glucose (mean of 4 
measurements), insulin (mean of 2 measurements), glucagon (mean of 2 measurements), free 
fatty acid (mean of 2 measurements) and ketone concentration (mean of 3 measurements) at 
baseline. On day 1, subjects were started on empagliflozin (25 mg/day) for 14 days. On day 1 
and day 14, fasting plasma glucose, insulin, glucagon, free fatty acid and ketone concentrations 
were repeated. The study was approved by UTHSCSA Institutional Review Board and informed 
written consent was obtained from all participants before the start of the study. 
Analytical Methods 
Plasma glucose was measured by glucose oxidase method (Beckman Instruments, 
Fullerton, CA). Plasma insulin was measured by radioimmunoassay (Diagnostic Products Corp., 
Los Angeles, CA). Plasma FFA was determined by enzymatic colorimetric quantification 
method (Wako Chemicals, Nuess, Germany). Plasma ketone concentration (beta hydroxyl 
butyrate and aceto-acetate) was measured by commercially available kit (Caymann Chemical, 
MI, USA). 
Calculations and statistical analysis 
The Ketogenic Index: to generate and index that predicts the risk of increase in plasma ketone 
concentration after empagliflozin administration, we examined the correlation, in the entire 
cohort, between plasma ketone concentration and plasma glucose concentration before and 1 day 
after empagliflozin treatment, plasma insulin, glucagon and FFA concentration at day 1 after 
empagliflozin treatment. Fasting plasma insulin and the decrease in plasma glucose 
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concentration significantly and inversely correlated with plasma ketone concentration while 
plasma FFA concentration significantly correlated with plasma ketone concentration. Thus, we 
defined the Ketogenic Index = log [FFA X (1/FPI) X (FPGpre/FPGtreat)].  
FFA= plasma free fatty acid concentration (in mM) after starting treatment; FPI= fasting plasma 
insulin concentration (µU/ml ) after starting treatment; FPGpre = fasting plasma glucose 
concentration (mg/dl) before starting treatment with empagliflozin; and FPGtreat = fasting plasma 
glucose concentration at day 1 after starting treatment with empagliflozin. 
The addition of plasma glucagon concentration to the index did not significantly improve its 
correlation with plasma ketone concentration. 
Values are presented as mean ± S.E.M. The difference between means was compared with 
ANOVA.  Correlation between variables was tested with Pearson’s correlation. Significance was 
set at p<0.05. 
 
RESULTS 
 
Table 1 presents clinical characteristics of study participants.  
Empagliflozin caused 45±4, 50±5 and 97±11 grams glucosuria per day in NGT, IFG and T2DM 
subjects, respectively. As anticipated, empagliflozin caused 26 and 38 mg/dl reduction in the 
FPG concentration at day 1 and day 14, respectively, (both p<0.0001), in T2DM patients. 
Conversely, the fasting plasma glucose concentration in NGT subjects was not affected by 
empagliflozin treatment (95 mg/dl vs 96 and 94 mg/dl before and at day 1 and 14 after treatment, 
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respectively) despite 45 grams per day of urinary glucose loss. Although urinary glucose loss 
was comparable in IFG subjects and NGT subjects, empagliflozin caused a modest but 
significant reduction in the FPG concentration (from 110±2 to 104±3 mg/dl, p<0.01) in IFG 
subjects. Further, the magnitude of decrease in the FPG concentration strongly and inversely 
correlated with the FPG concentration (r=-0.80, p<0.0001) (Figure 1) and this relationship was 
maintained in non-diabetic subjects (r=-0.61, p<0.01).  
As anticipated and consistent with previous studies (6-9), empagliflozin caused a significant 
decrease (by 27%, p=0.05) in the fasting plasma insulin concentration and a large increase in the 
fasting plasma glucagon concentration at day 1 in T2DM patients (Table 2). The increase in 
fasting plasma glucagon was maintained at day 14, however, the FPI concentration returned to 
the pretreatment level at day 14. Conversely, empagliflozin did not significantly affect the 
fasting plasma insulin and glucagon concentrations in NGT and IFG subjects.  
Fasting plasma FFA was 543±68, 467±37 and 740±57 µM in NGT, IFG and T2DM patients 
respectively, and increased similarly in all 3 groups  in day 1 (p=0.01), but returned back to the 
pretreatment level at day 14 in all 3 groups.  
Consistent with previous studies (10,11), empagliflozin caused a significant increase in fasting 
plasma ketone concentration in T2DM patients (from 528±36 to 670±49 µM in day 14, p=0.03), 
while plasma ketone concentration was not affected by empagliflozin treatment in either IFG 
(436±31 vs 421±32) or NGT (537±64 vs 451±32 µM) subjects following empagliflozin 
treatment (Figure 2). 
Relationship between plasma ketone, insulin, glucose, and FFA concentration 
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The magnitude of decrease in plasma glucose concentration at day 1 did not significantly 
correlate with the change in plasma insulin, glucagon or FFA concentration at day 1. However, it 
significantly and inversely correlated with the plasma ketone concentration at day 1 (r=-0.63, 
p<0.05) and the increase in plasma ketone concentration from baseline to day 1, (r=-0.74, 
p=0.01) (Figure 3). The plasma ketone concentration at day 1 strongly correlated with plasma 
FFA concentration at day 1 (r=0.59, p<0.05) and inversely correlated with plasma insulin 
concentration at day 1 (r=-0.51, p<0.05). As anticipated, the decrease in plasma insulin 
concentration was associated with an increase in plasma FFA concentration (r=-0.55, p=0.01). 
The ketogenic index strongly correlated with plasma ketone concentration at day 1 (r=0.85, 
p<0.001)), day 14 (r=0.64, p=0.01) and a cut point of -0.9 predicted subjects in the upper tertile 
(with plasma ketone concentration >0.6 mM, mean=0.76 mM) with 86% sensitivity and 83% 
specificity.      
 
 
DISCUSSION 
The present study has several novel observations. Unlike subjects with T2DM, emagliflozin did 
not affect the fasting plasma glucose concentration in NGT subjects despite large glucosuria (50 
grams per day). Moreover, although glucosuria caused by empagliflozin in IFG was comparable 
to that in NGT, empagliflozin caused a small but significant decrease in the FPG concentration  
in IFG subjects. Further, the magnitude of decrease in the FPG concentration strongly and 
inversely correlated with the fasting plasma glucose concentration in the entire cohort and this 
relationship was maintained in non-diabetic individuals. The strong relationship between the 
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magnitude of decrease in the FPG concentration and the FPG level in diabetic subjects can be 
explained by the fact that more glucose is removed from the body by SGLT2 inhibition as the 
FPG concentration increases and more glucose is filtered in the glumerolus (12). However, the 
differential effect of empagliflozin on the FPG concentration between IFG and NGT subjects can 
not be explained by differences in the amount of glucose removed by the kidney since it was 
comparable between both groups. Previous study with dapagliflozin in NGT subjects has 
reported no effect of the drug on the FPG concentration over 14 days treatment (13). These 
results suggest that it is likely that the decrease in FPG concentration in IFG subjects by 
empagliflozin is not simply due to urinary glucose loss, rather it is likely to correction of some of 
the underlying mechanisms responsible for the rise in FPG concentration in IFG subjects (14).  
Although not measured in the present study, the basal rate of hepatic glucose production (HGP) 
has to increase following empagliflozin administration to compensate for the large urinary 
glucose loss in non-diabetic individuals and maintain the FPG concentration at euglycemia. A 
recent study (11) has reported even greater increase (32%) in bHGP in non-diabetic than in 
diabetic (24%) individuals following 4-week empagliflozin treatment. Nonetheless, unlike in 
T2DM patients, empagliflozin did not significantly affect the FPI or fasting plasma glucagon 
concentration in non-diabetic individuals. This finding is surprising and argues against an 
important role of increase in plasma glucagon concentration in the stimulation of bHGP in 
T2DM following SGLT2 administration in T2DM patients (7,9). Recent study (15) reported the 
presence of SGLT2 in alpha cell and suggested that inhibition of SGLT2 in the alpha cell with 
dapagliflozin strongly stimulates glucagon secretion. The results of the present study 
demonstrate that in the absence of change in the fasting plasma glucose concentration, e.g. in 
NGT individuals, empagliflozin did not affect glucagon secretion, suggesting that, at least in 
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vivo in man, the decrease in the FPG concentration subsequent to urinary glucose loss plays 
more important role in simulating glucagon secretion than direct effect of the drug on the alpha 
cell.  
The increase in plasma ketone concentration strongly and inversely correlated with the decrease 
in plasma glucose concentration. The increase in plasma ketone concentration also strongly 
correlated with plasma FFA concentration and inversely correlated with fasting plasma insulin 
concentration at day 1. Further, the ketogenic index strongly correlated with plasm ketone 
concentration in day 1 and day 14. The increase in fasting plasma FFA concentration explains, at 
least in part, the increase in fat oxidation caused by SGLT2 inhibitor which was reported in 
previous studies (10, 11) which could lead to increase in ketone production. Because insulin is 
very powerful inhibitor of lipolysis (16), the decrease in fasting plasma insulin explains the 
increase in plasma FFA concentration and indeed the increase in plasma FFA concentration 
strongly and inversely correlated with the decrease in plasma insulin concentration (r=-0.55, 
p=0.01). These results suggest that the decrease in FPG concentration caused by glucosuria is 
likely the primary factor which triggers the other metabolic actions of SGLT2 inhibitors. The 
decrease in FPG concentration stimulates glucagon secretion and inhibits insulin secretion. 
Because of the powerful inhibitory effect of insulin on lipolysis, the decrease in FPI 
concentration results in an increase in plasma FFA and subsequent increase in fat oxidation and 
ketone production. Thus, the ketogenic index, which integrates the decrease in plasma glucose 
and insulin concentrations and increase in plasma FFA concentration, strongly correlated with 
plasma ketone concentration at day 1 and day 14 after empagliflozin administration, and 
predicted with high sensitivity and sensitivity subjects in whom the increase in plasma ketone 
concentration was in the top tertile. Thus, it will be of great interest to examine whether therapies 
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which stimulate insulin secretion and decrease plasma FFA concentration, e.g. GLP-1 RA and 
pioglitazone, will mitigate the increase in ketone production and risk of ketoacidosis caused by 
SGLT2 administration.   
In summary, the results of the present study demonstrate that it is likely that the change in 
plasma insulin and glucagon concentrations after SGLT2 is secondary to the decrease in FPG, 
and it does not play important role in stimulating HGP, but result in increase in FFA and 
stimulation of ketone production.       
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Figure 1: relationship between the decrease in fasting plasma glucose concentration at day 14 by 
empagliflozin and the fasting plasma glucose concentration before the start of treatment 
Figure 2: Plasma ketone concentration before, at day 1 and day 14 after treatment with 
empagliflozin in NGT, IFG and T2DM patients 
Figure 3: Relationship between the change in plasma glucose concentration and change in 
plasma ketone concentration after treatment with dapagliflozin in NGT, IFG and T2DM patients 
Figure 4: Relationship between the ketogenic index and plasma ketone concentration at day 1 
after treatment with empagliflozin in in NGT, IFG and T2DM patients. 
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Table 1: Baseline patient characteristics 
 NFG IFG T2DM P 
Age (years) 58±2 59±3 55±2 NS 
Gender (m/f) 6/2 5/3 12/3 NS 
BMI (kg/m2) 27.0±1.1 30.3±0.8 31.1±2.1 0.04 
FPG (mg/dl) 95±2 110±2 195±9 <0.0001 
HbA1c (%) 5.6±0.1 5.7±0.1 7.8±0.2 P<0.0001 
Plasma Creatinine 
(mg/dl) 
0.70±0.05 0.79±0.04 0.8±.005 NS 
eGFR (ml/min.1.73 
m2) 
120±10 99±6 107±7 NS 
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Table 2: Fasting plasma glucose, insulin, glucagon and FFA before, and at day 1 and day 14 after treatment with empagliflozin.   
 NGT IFG Non-Diabetic (IFG+NGT) T2DM 
 Baseline Day 1 Day 14 Baseline Day 1 Day 14 Baseline Day 1 Day 14 Baseline Day 1 Day 14 
FPG 
(mg/dl) 
95±1 96±3 94±3 110±2 105±3* 104±3* 103±2 101±2 99±3 195±9 169±11* 157±8* 
FPI (µU/ml) 9±2 9±2 12±3 19±2 18±2 17±2 14±2 14±2 15±2 15±3 11±2* 15±2 
Glucagon 
(ng/l) 
69±2 75±6 74±9 86±5 97±9 79±6 78±5 86±6 77±5 94±12 120±19* 106±11* 
FFA (µM) 543±68 650±88 417±52 467±37 615±90 491±41 504±40 633±63* 454±63 740±57 885±42* 762±47 
Ketone (µM) 537±64 492±40 451±32 436±31 443±29 421±32 487±38 468±26 437±22 528±36 667±49* 670±100*
*P<0.05 
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